# Hryz Bio Tech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hryz-bio-tech

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.shhryz.com
- Total disclosed funding: $43M
- Latest round: Series C (Jan 9, 2024)
- Investors on record: 9

## About

Based in Shenzhen, China and founded in 2015, Hengrui Yuanzheng (Shanghai) Biotechnology Co.,Ltd., dba Hryz Bio Tech, is a biotechnology company focused on the development of immune cell therapy technology for solid tumors. The company is headquartered in Shanghai and has wholly-owned subsidiaries in Shenzhen and Guangzhou. It has applied for 46 patents of various types and has been granted 15 authorizations through PCT applications in China, the United States, Japan, Russia, and Israel. It has 10 doctoral talents, more than 50 master talents and 7 returnees. Furthermore, it passed ISO9001, ISO14001 and OHSAS18001 management system certifications in 2016 and is building a headquarters base in Songjiang, Shanghai and a regional cell preparation center in the Yangtze River Delta in 2021. In February 2026, Hryz Bio Tech closed a venture funding from Shengdi Investment and Yinglian Health Industry Fund.

Based on the Reverse Genetic Engineering TCR Screening Technology Platform (ReGET), Hryz Bio Tech develops MASCT (Multi-Antigen Stimulated Cell Therapy Injection) products, TCR-T (T Cell Receptor-Gene Engineered T Cells) immune cell products, and TCR dual antibody products. Its TCR-T product HRYZ-T101 can be used to treat cervical cancer.

## Funding rounds

- Series C, Jan 9, 2024, $14M — Goldport Capital, China Science and Tech Innovation Venture Capital
- Series C, May 12, 2023, $29M — Goldport Capital, China Science and Tech Innovation Venture Capital, Jiangsu Hengrui Medicine Co.,Ltd.
- Series B, Dec 28, 2020 — Sincere Capital, China Science and Tech Innovation Venture Capital, Lingyi Jinfu
- Series A, Sep 2, 2020 — China International Capital Corporation, HTHS Capital, Jinliang Qide (Xiamen) Investment, Beijing Huaheng Shengyu Investment

## Investors

- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series A
- HTHS Capital (https://capitalatlas.ai/funds/hths-capital) — Series A
- Jinliang Qide (Xiamen) Investment — Series A
- Beijing Huaheng Shengyu Investment — Series A
- Sincere Capital (https://capitalatlas.ai/funds/sincere-capital) — Series B
- China Science and Tech Innovation Venture Capital (https://capitalatlas.ai/funds/china-science-and-tech-innovation-venture-capital) — Series B, Series C
- Lingyi Jinfu (https://capitalatlas.ai/funds/lingyi-jinfu) — Series B
- Goldport Capital (https://capitalatlas.ai/funds/goldport-capital) — Series C
- Jiangsu Hengrui Medicine Co.,Ltd. — Series C